Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer

Study Of The Expression Of Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02869282

Acronym

CHEMOPROST

Enrollment

Registered

2016-08-16

Start date

2011-06-30

Completion date

2016-12-31

Last updated

2025-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

Multicentric, observational, prospective, non-interventional study with occasional biological sample collection (serum bank, urine bank and tumor bank)

Detailed description

This project is an exploratory study, based on the hypothesis of involvement of chemokines in hormonal escape of prostate cancers. The two main objectives are: * To describe the variations in expression of chemokines in serum and urine level in patients with prostate cancer * And to study the disease stage and intra-prostatic concentrations of chemokines based on serum and urine concentrations of chemokines before treatment initiation. These estimates can be used in future trials set up for the management of prostate cancer

Interventions

OTHERBlood samples

Additional blood samples at baseline, 6, 12, 18 and 24 months.

OTHERUrine samples

Additional urine samples at baseline, 6, 12, 18 and 24 months.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with a localized or metastatic prostate adenocarcinoma for which a new treatment will be implemented (hormone therapy for single biological relapse or relapses and metastatic hormone-sensitive) or chemotherapy (for biological relapses and / or metastatic hormone-resistant) * Patients with a detectable PSA (Prostate-Specific Antigen) * Patients who signed an informed consent * Patients over 18 years * Patients belonging to the social security scheme

Exclusion criteria

* Active Hepatitis B or C virus * HIV positive * Patients who have received prior chemotherapy * Patients with a second neoplasia treated in the last 5 years

Design outcomes

Primary

Measure	Time frame
Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical	At baseline

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026